Maryam Tabatabai, PharmD, associate vice president of clinical information, offers predictions about forthcoming drug approvals, the latest on a new voucher pilot, updated biosimilar guidance and more

Jessica Johnson, clinical consultant at Prime Therapeutics, shares more about common GLP-1 fraud schemes

GLP-1 year two cost effectiveness study abstract

Real-world study of GLP-1 patients continues to deliver leading insights

Findings also show improved persistence with high-potency, obesity-approved GLP-1 products

publications The evolution of GLP-1s July 31, 2025 Prime's clinical experts share their perspectives on developing a holistic, individualized strategy to capitalize on opportunities and improve...

Prime's recent analysis shows that patients with obesity stopped using a GLP-1 medication within the first few years of treatment.

Among the key findings from the study — among 4,066 members, Prime/MRx found 1 in 3 stayed on their GLP-1 and 27% took their medication as intended